<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04050189</url>
  </required_header>
  <id_info>
    <org_study_id>2020-3242</org_study_id>
    <nct_id>NCT04050189</nct_id>
  </id_info>
  <brief_title>Validation of the In-utero Transmission of Probiotics</brief_title>
  <acronym>PROBIO</acronym>
  <official_title>Validation of the In-utero Transmission of Probiotics From the Mother to the Baby: A Randomized Crossover Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre de recherche du Centre hospitalier universitaire de Sherbrooke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lallemand Health Solutions</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre de recherche du Centre hospitalier universitaire de Sherbrooke</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot project aims at confirming the in-utero transmission of probiotics, from the&#xD;
      mother to the baby. Women aged 18 to 42 years, with a single pregnancy, considered low risk&#xD;
      will be approached for this study. Women will take the investigational products between 34&#xD;
      weeks of pregnancy up to 10 days post-partum. Investigational products are probiotics (5&#xD;
      bacterial strains) compared to placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rational: Studies have shown that probiotics given to babies can reduce perinatal&#xD;
      complications. A change of practice should therefore be introduced in the management of&#xD;
      premature newborns. However, one could assume that probiotic administration before birth&#xD;
      could be as effective if not more. Indeed, one could hypothesise that when the newborn is&#xD;
      exposed to probiotics earlier, the protective effect is potentially increased.&#xD;
&#xD;
      Objective: This pilot project aims at confirming the in-utero transmission of probiotics,&#xD;
      from the mother to the baby.&#xD;
&#xD;
      Population: Women aged 18 to 42 years, with a single pregnancy, considered low risk will be&#xD;
      approached for this study Products under study: Probiotics containing 5 bacterial strains&#xD;
      (total of 12 million colony-forming unit / day) vs. Placebo.&#xD;
&#xD;
      Procedure: At 32-33 weeks, participants will complete questionnaires (medical, obstetrical,&#xD;
      socio-demographic data) and will be randomized (double-blind) in one of the 2 following&#xD;
      groups:&#xD;
&#xD;
      Group A: taking probiotics every day from the 34th week of pregnancy until delivery; taking&#xD;
      placebo for 10 days after delivery.&#xD;
&#xD;
      Group B: taking placebo every day from the 34th week of pregnancy until delivery; taking&#xD;
      probiotics for 10 days after delivery.&#xD;
&#xD;
      Follow-up: All women will complete a logbook to monitor the study products intake and monitor&#xD;
      side effects until the end of the study (10 days postpartum).&#xD;
&#xD;
      Samples: maternal stool samples, vaginal secretions, stool (and meconium) as well as breast&#xD;
      milk (and colostrum) will be taken at different times of the study to confirm the presence of&#xD;
      probiotics and transmission between the mother and the baby.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 30, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>2-arms randomized crossover pilot study</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>double-blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>in-utero transmission of probiotic</measure>
    <time_frame>at birth</time_frame>
    <description>presence (yes or no) of probiotic (specific bacterial strains) in neonate meconium</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>transmission of probiotic to colostrum</measure>
    <time_frame>at birth</time_frame>
    <description>presence(yes or no) of probiotic (specific bacterial strains) in colostrum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>transmission of probiotic to maternal milk</measure>
    <time_frame>10 days postpartum</time_frame>
    <description>presence (yes or no) of probiotic (specific bacterial strains) in breastmilk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>transmission of probiotic to maternal vaginal tract</measure>
    <time_frame>37 weeks of gestation</time_frame>
    <description>presence (yes or no) of probiotic (specific bacterial strains) in maternal vaginal swab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>transmission of probiotic to maternal gut</measure>
    <time_frame>37 weeks of gestation</time_frame>
    <description>presence (yes or no) of probiotic (specific bacterial strains) in maternal stools</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postnatal transmission of probiotic to the neonate</measure>
    <time_frame>10 days postpartum</time_frame>
    <description>presence (yes or no) of probiotic (specific bacterial strains) in neonate stools</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>In Utero Drug Exposure</condition>
  <arm_group>
    <arm_group_label>prenatal probiotic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>will take probiotics every day from the 34th week of pregnancy until delivery; taking placebo for 10 days after delivery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>postnatal probiotic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>will take placebo every day from the 34th week of pregnancy until delivery; taking probiotics for 10 days after delivery</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Natural products: Probiotics</intervention_name>
    <description>Probiotics intake every day (1.5 gram) from 34 weeks of gestation to delivery OR from delivery to 10 days postpartum</description>
    <arm_group_label>postnatal probiotic</arm_group_label>
    <arm_group_label>prenatal probiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo intake every day (1.5 gram) from 34 weeks of gestation to delivery OR from delivery to 10 days postpartum</description>
    <arm_group_label>postnatal probiotic</arm_group_label>
    <arm_group_label>prenatal probiotic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women with a single pregnancy&#xD;
&#xD;
          -  Women with a low risk pregnancy&#xD;
&#xD;
          -  Women wishing to breastfeed at birth&#xD;
&#xD;
          -  Women randomized between 32 0/7 - 33 6/7 weeks of gestation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of obstetric complications (prematurity &lt;37 weeks, severe preeclampsia ,&#xD;
             gestational diabetes treated with insulin)&#xD;
&#xD;
          -  Obstetric or fetal complications known for current pregnancy such as threaten preterm&#xD;
             labor (premature rupture of membranes or preterm labor), chorioamnionitis, placenta&#xD;
             previa, active vaginal bleeding, cervical cerclage, fetal distress or anomalies,&#xD;
             corticosteroid therapy&#xD;
&#xD;
          -  Risk factors for obstetric complications during current pregnancy such as gestational&#xD;
             diabetes, type I / II diabetes and high blood pressure (systole ≥140 and diastole ≥90)&#xD;
&#xD;
          -  Antibiotic use within 2 weeks before randomisation&#xD;
&#xD;
          -  Intake of probiotics or foods enriched with active cultures (fermented milk, kefir,&#xD;
             kombucha ...) within 2 weeks before randomisation&#xD;
&#xD;
          -  Women positive for Group B Streptococcus during previous pregnancies&#xD;
&#xD;
          -  Weakened immune system (AIDS, lymphoma, chemoradiotherapy or corticotherapy,&#xD;
             immunosuppressive pathology)&#xD;
&#xD;
          -  Allergy or intolerance to lactose, soy or yeast.&#xD;
&#xD;
          -  Women under Coumadin&#xD;
&#xD;
          -  Women who plan to give birth outside the participating center&#xD;
&#xD;
          -  Women who do not plan to breastfeed or extract their milk in the first 10 days after&#xD;
             delivery.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Charles Pasquier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CIUSSS-Estrie-CHUS hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amelie Tetu</last_name>
    <phone>8193461110</phone>
    <phone_ext>15571</phone_ext>
    <email>amelie.tetu.ciussse-chus@ssss.gouv.qc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Audrey Hamel-Thibault</last_name>
    <phone>8193461110</phone>
    <phone_ext>12865</phone_ext>
    <email>Audrey.Hamel-Thibault@USherbrooke.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CIUSSS de L'Estrie-CHUS Hospital</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Amelie Tetu</last_name>
      <phone>8193461110</phone>
      <phone_ext>15571</phone_ext>
      <email>amelie.tetu.ciussse-chus@ssss.gouv.qc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Audrey Hamel-Thibault</last_name>
      <phone>8193461110</phone>
      <phone_ext>12865</phone_ext>
      <email>Audrey.Hamel-Thibault@USherbrooke.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Jean-Charles Pasquier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Francois Beaulieu, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 5, 2019</study_first_submitted>
  <study_first_submitted_qc>August 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2019</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>probiotic</keyword>
  <keyword>in-utero transmission</keyword>
  <keyword>pilot study</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>This is a pilot study. Samples and data will be used to confirm the principal hypothesis and explorative secondary objectives.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

